BIOGEN INC. Available-for-sale Securities, Gross Realized Losses
BIOGEN INC. (BIIB) reported Available-for-sale Securities, Gross Realized Losses of $1.50 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-06.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses · last filed 2020-02-06
- BIOGEN INC. available-for-sale securities, gross realized losses for the quarter ending 2018-03-31 was $9.40M, a 394.74% increase year-over-year.
- BIOGEN INC. available-for-sale securities, gross realized losses for the quarter ending 2017-12-31 was $18.00M, a 1025.00% increase year-over-year.
- BIOGEN INC. available-for-sale securities, gross realized losses for the quarter ending 2017-09-30 was $1.20M, a 9.09% increase year-over-year.
- BIOGEN INC. available-for-sale securities, gross realized losses for the quarter ending 2017-06-30 was $1.30M, a 8.33% increase year-over-year.
- BIOGEN INC. available-for-sale securities, gross realized losses for fiscal 2019 was $1.50M, a 87.18% decline from fiscal 2018.
- BIOGEN INC. available-for-sale securities, gross realized losses for fiscal 2018 was $11.70M, a 47.77% decline from fiscal 2017.
- BIOGEN INC. available-for-sale securities, gross realized losses for fiscal 2017 was $22.40M, a 420.93% increase from fiscal 2016.
- BIOGEN INC. available-for-sale securities, gross realized losses for fiscal 2016 was $4.30M, a 22.86% increase from fiscal 2015.
| Period end | Available-for-sale Securities, Gross Realized Losses 3 month | Available-for-sale Securities, Gross Realized Losses 3 month as first filed | Available-for-sale Securities, Gross Realized Losses 6 month | Available-for-sale Securities, Gross Realized Losses 6 month as first filed | Available-for-sale Securities, Gross Realized Losses 9 month | Available-for-sale Securities, Gross Realized Losses 12 month |
|---|---|---|---|---|---|---|
| 2019-12-31 | $1.50M 10-K · filed 2020-02-06 | |||||
| 2018-12-31 | $11.70M 10-K · filed 2020-02-06 | |||||
| 2018-03-31 | $9.40M 10-Q · filed 2018-04-24 | $27.40M derived: sum of 2 quarters · filed 2020-02-06 | $28.60M derived: sum of 3 quarters · filed 2020-02-06 | $29.90M derived: sum of 4 quarters · filed 2020-02-06 | ||
| 2017-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $19.20M derived: sum of 2 quarters · filed 2020-02-06 | $20.50M derived: sum of 3 quarters · filed 2020-02-06 | $22.40M 10-K · filed 2020-02-06 | ||
| 2017-09-30 | $1.20M 10-Q · filed 2017-10-24 | $2.50M derived: sum of 2 quarters · filed 2017-10-24 | $4.40M 10-Q · filed 2017-10-24 | $6.00M derived: sum of 4 quarters · filed 2019-02-06 | ||
| 2017-06-30 | $1.30M 10-Q · filed 2017-07-25 | $3.20M 10-Q · filed 2017-07-25 | $4.80M derived: sum of 3 quarters · filed 2019-02-06 | $5.90M derived: sum of 4 quarters · filed 2019-02-06 | ||
| 2017-03-31 | $1.90M 10-Q · filed 2018-04-24 | $3.50M derived: sum of 2 quarters · filed 2019-02-06 | $4.60M derived: sum of 3 quarters · filed 2019-02-06 | $5.80M derived: sum of 4 quarters · filed 2019-02-06 | ||
| 2016-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | $2.70M derived: sum of 2 quarters · filed 2019-02-06 | $3.90M derived: sum of 3 quarters · filed 2019-02-06 | $4.30M 10-K · filed 2019-02-06 | ||
| 2016-09-30 | $1.10M 10-Q · filed 2017-10-24 | $2.30M derived: sum of 2 quarters · filed 2017-10-24 | $2.70M 10-Q · filed 2017-10-24 | $3.30M derived: sum of 4 quarters · filed 2018-02-01 | ||
| 2016-06-30 | $1.20M 10-Q · filed 2017-07-25 | $1.60M 10-Q · filed 2017-07-25 | $2.20M derived: sum of 3 quarters · filed 2018-02-01 | $4.20M derived: sum of 4 quarters · filed 2018-02-01 | ||
| 2016-03-31 | $400.00K 10-Q · filed 2017-04-25 | $1.00M derived: sum of 2 quarters · filed 2018-02-01 | $3.00M derived: sum of 3 quarters · filed 2018-02-01 | $3.50M derived: sum of 4 quarters · filed 2018-02-01 | ||
| 2015-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $2.60M derived: sum of 2 quarters · filed 2018-02-01 | $3.10M derived: sum of 3 quarters · filed 2018-02-01 | $3.50M 10-K · filed 2018-02-01 | ||
| 2015-09-30 | $2.00M 10-Q · filed 2016-10-26 | $2.50M derived: sum of 2 quarters · filed 2016-10-26 | $2.90M 10-Q · filed 2016-10-26 | $3.00M derived: sum of 4 quarters · filed 2017-02-02 | ||
| 2015-06-30 | $500.00K 10-Q · filed 2016-07-21 | $800.00K 10-Q · filed 2016-07-21 | $1.00M derived: sum of 3 quarters · filed 2017-02-02 | $1.10M derived: sum of 4 quarters · filed 2017-02-02 | ||
| 2015-03-31 | $300.00K 10-Q · filed 2016-04-21 | $500.00K derived: sum of 2 quarters · filed 2017-02-02 | $600.00K derived: sum of 3 quarters · filed 2017-02-02 | $700.00K derived: sum of 4 quarters · filed 2017-02-02 | ||
| 2014-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $300.00K derived: sum of 2 quarters · filed 2017-02-02 | $400.00K derived: sum of 3 quarters · filed 2017-02-02 | $500.00K 10-K · filed 2017-02-02 | ||
| 2014-09-30 | $100.00K 10-Q · filed 2015-10-21 | $200.00K derived: sum of 2 quarters · filed 2015-10-21 | $300.00K 10-Q · filed 2015-10-21 | $300.00K derived: sum of 4 quarters · filed 2016-02-03 | ||
| 2014-06-30 | $100.00K 10-Q · filed 2015-07-24 | $200.00K 10-Q · filed 2015-07-24 | $200.00K derived: sum of 3 quarters · filed 2016-02-03 | $200.00K derived: sum of 4 quarters · filed 2016-02-03 | ||
| 2014-03-31 | $100.00K 10-Q · filed 2015-04-24 | $100.00K derived: sum of 2 quarters · filed 2016-02-03 | $100.00K derived: sum of 3 quarters · filed 2016-02-03 | $100.00K derived: sum of 4 quarters · filed 2016-02-03 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $0.00 derived: sum of 2 quarters · filed 2016-02-03 | $0.00 derived: sum of 3 quarters · filed 2016-02-03 | $2.10M 10-K · filed 2016-02-03 | ||
| 2013-09-30 | $0.00 10-Q · filed 2014-10-22 | $0.00 derived: sum of 2 quarters · filed 2014-10-22 | $2.10M 10-Q · filed 2014-10-22 | $2.80M derived: sum of 4 quarters · filed 2015-02-04 | ||
| 2013-06-30 | $0.00 10-Q · filed 2014-07-23 | $2.00M 10-Q · filed 2014-07-23 | $2.80M derived: sum of 3 quarters · filed 2015-02-04 | $3.60M derived: sum of 4 quarters · filed 2015-02-04 | ||
| 2013-03-31 | $2.00M 10-Q · filed 2014-04-23 | $2.80M derived: sum of 2 quarters · filed 2015-02-04 | $3.60M derived: sum of 3 quarters · filed 2015-02-04 | $4.90M derived: sum of 4 quarters · filed 2015-02-04 | ||
| 2012-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $1.60M derived: sum of 2 quarters · filed 2015-02-04 | $2.90M derived: sum of 3 quarters · filed 2015-02-04 | $3.50M 10-K · filed 2015-02-04 | ||
| 2012-09-30 | $800.00K 10-Q · filed 2013-10-28 | $2.10M derived: sum of 2 quarters · filed 2013-10-28 | $2.70M 10-Q · filed 2013-10-28 | $3.40M derived: sum of 4 quarters · filed 2014-02-06 | ||
| 2012-06-30 | $1.30M 10-Q · filed 2013-07-25 | $2.00M 10-Q · filed 2013-07-25 | $2.60M derived: sum of 3 quarters · filed 2014-02-06 | $3.00M derived: sum of 4 quarters · filed 2014-02-06 | ||
| 2012-03-31 | $700.00K 10-Q · filed 2013-04-25 | $1.30M derived: sum of 2 quarters · filed 2014-02-06 | $1.70M derived: sum of 3 quarters · filed 2014-02-06 | $2.20M derived: sum of 4 quarters · filed 2014-02-06 | ||
| 2011-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $1.00M derived: sum of 2 quarters · filed 2014-02-06 | $1.50M derived: sum of 3 quarters · filed 2014-02-06 | $2.30M 10-K · filed 2014-02-06 | ||
| 2011-09-30 | $400.00K 10-Q · filed 2012-10-25 | $900.00K derived: sum of 2 quarters · filed 2012-10-25 | $1.70M 10-Q · filed 2012-10-25 | $2.20M derived: sum of 4 quarters · filed 2013-02-05 | ||
| 2011-06-30 | $500.00K 10-Q · filed 2012-07-24 | -$500.00K 10-Q · filed 2011-07-26 | $1.30M 10-Q · filed 2012-07-24 | -$1.30M 10-Q · filed 2011-07-26 | $1.80M derived: sum of 3 quarters · filed 2013-02-05 | $2.00M derived: sum of 4 quarters · filed 2013-02-05 |
| 2011-03-31 | $800.00K 10-Q · filed 2012-05-01 | -$800.00K 10-Q · filed 2011-04-21 | $1.30M derived: sum of 2 quarters · filed 2013-02-05 | $1.50M derived: sum of 3 quarters · filed 2013-02-05 | $2.60M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2010-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $700.00K derived: sum of 2 quarters · filed 2013-02-05 | $1.80M derived: sum of 3 quarters · filed 2013-02-05 | $2.50M 10-K · filed 2013-02-05 | ||
| 2010-09-30 | $200.00K 10-Q · filed 2011-10-28 | $1.30M derived: sum of 2 quarters · filed 2011-10-28 | $2.00M 10-Q · filed 2011-10-28 | $2.60M derived: sum of 4 quarters · filed 2012-02-03 | ||
| 2010-06-30 | $1.10M 10-Q · filed 2011-07-26 | $1.80M 10-Q · filed 2011-07-26 | $2.40M derived: sum of 3 quarters · filed 2012-02-03 | $3.70M derived: sum of 4 quarters · filed 2012-02-03 | ||
| 2010-03-31 | $700.00K 10-Q · filed 2011-04-21 | $1.30M derived: sum of 2 quarters · filed 2012-02-03 | $2.60M derived: sum of 3 quarters · filed 2012-02-03 | $3.20M derived: sum of 4 quarters · filed 2012-02-03 | ||
| 2009-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $1.90M derived: sum of 2 quarters · filed 2012-02-03 | $2.50M derived: sum of 3 quarters · filed 2012-02-03 | $4.00M 10-K · filed 2012-02-03 | ||
| 2009-09-30 | $1.30M 10-Q · filed 2010-10-26 | $1.90M derived: sum of 2 quarters · filed 2010-10-26 | $3.40M 10-Q · filed 2010-10-26 | |||
| 2009-06-30 | $600.00K 10-Q · filed 2010-07-20 | $2.00M 10-Q · filed 2010-07-20 | ||||
| 2008-12-31 | $17.00M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |